- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
Pfizer Receives FDA Accelerated Approval for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults10/29/14 2:44 pm EDT
TRUMENBA is the First and Only Approved Vaccine in the U.S. for the Prevention of Meningococcal Meningitis BNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TRUMENBA® (meningococcal group B vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. Approval of TRUMENBA is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strainsmore...
Pfizer’s PRISTIQ® (desvenlafaxine) Demonstrates Low Potential For Sexual Dysfunction in Adults with Major Depressive Disorder10/29/14 8:30 am EDT
Study Also Reinforces Existing Body of Clinical Evidence in Support of the Efficacy, Safety and Tolerability Profiles of PRISTIQNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the publication of a clinical study in the Journal of Clinical Psychiatry showing comparable sexual function in adult patients diagnosed with major depressive disorder (MDD) treated daily with PRISTIQ Extended Release Tablets 50mg and 100mg doses versus placebo. Sexual dysfunction is often an issue for patients treated with antidepressants, and Pfizer conducted the study pursuant to a postmarketingmore...
10/28/14 7:00 am EDT
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) reported financial results for third-quarter 2014. At the beginning of fiscal year 2014, the company began managing its commercial operations through a new global commercial structure consisting of three operating segments: the Global Innovative Pharmaceutical segment (GIP)(3); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC)(3); and the Global Established Pharmaceutical segment (GEP)(3).more...
- Third-Quarter 2014 Reported Revenues(1) of $12.4 Billion
- Third-Quarter 2014 Adjusted Diluted EPS(2) of $0.57, Reported Diluted EPS(1) of $0.42
- Repurchased $4.2 Billion of Common Stock to Date in 2014
- Updated Ranges for Certain 2014 Financial Guidance Components
10/27/14 8:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) has notified Pain Therapeutics, Inc. (NASDAQ: PTIE) that it has decided to discontinue its agreement to develop and commercialize REMOXY™ (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics, Inc. Pfizer has concluded an internal review of the top-more...
10/23/14 4:05 pm EDT
Board of Directors Authorizes New $11 Billion Share Repurchase ProgramNEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 26-cent fourth-quarter 2014 dividend on the company’s common stock, payable December 2, 2014, to shareholders of record at the close of business on November 7, 2014. The fourth-quarter 2014 cash dividend will be the 304th consecutive quarterly dividend paid by Pfizer. The board of directors also authorized a new $11 billion share repurchase program to be utilized over time. This newmore...
10/23/14 8:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT® (sunitinib malate) capsules. This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021. “The Court’s decision acknowledges the validity and infringement of ourmore...
FDA Approves Abuse Deterrent Labeling for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended-Release (ER) Capsules CII10/17/14 4:38 pm EDT
EMBEDA is the first and only approved ER morphine specifically designed to deter oral and intranasal abuse when crushedNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has approved an updated label for EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release (ER) capsules, for oral use, CII, to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal (i.e., snorting) routes when crushed. However, abuse ofmore...
10/13/14 8:00 am EDT
NDA Requests Approval of Palbociclib as a First-Line Therapy in Combination with Letrozole for ER+, HER2- Advanced Breast CancerNEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA). This NDA requests FDA approval of palbociclib, in combination with letrozole, as a first-line treatment for postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who havemore...
Pfizer to Present New Data Evaluating Safety, Tolerability and Immunogenicity of its Investigational Staphylococcus aureus Vaccine Candidate at IDWeek 2014™10/10/14 8:00 am EDT
Rapid and sustained response in functional antibody titers observed following single-dose administration of a novel, investigational 4-antigen Staphylococcus aureus vaccine (SA4Ag) to healthy adultsNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that it will present data from a Phase 1/Phase 2 study evaluating the safety, tolerability and immunogenicity of a single-dose vaccine of Pfizer’s investigational 4-antigen Staphylococcus aureus (S. aureus) candidate vaccine (SA4Ag) in healthy adults. The data will be presented at IDWeek 2014™ taking place Oct. 8-12, 2014 in Philadelphia, Pennsylvania. The SA4Ag vaccine candidate (PF-06290510),more...
Pfizer and Breast Cancer Leaders Join Together to Increase Understanding and Dispel Myths about Metastatic Breast Cancer10/8/14 8:30 am EDT
NEW YORK--(BUSINESS WIRE)--This October, Pfizer Inc. is uniting with leaders in the breast cancer community in a public call-to-action to expand the breast cancer dialogue to include metastatic breast cancer. This comes after a first-of-its-kind survey commissioned by Pfizer revealed that many people know little to nothing about metastatic breast cancer – the most advanced stage of breast cancer (Stage IV), in which cancer has spread beyond the breast to other organs inmore...
- Metastatic breast cancer currently affects 150,000-250,000 people in the U.S. and remains an incurable condition1,2
- New initiative aims to expand the breast cancer conversation to be more inclusive of metastatic disease